Bietti结晶样营养不良基因治疗后的安全性与视力结局:一项非随机临床试验
这项开放标签、剂量递增非随机临床试验在中国2个研究点纳入12例经基因确诊的Bietti结晶样营养不良(BCD)患者,行视网膜下注射rAAV2-hCYP4V2(1.5×10^11或3.0×10^11总载体基因组),随访12个月;未观察到与治疗相关的严重不良事件,1例出现轻度眼内炎症;研究眼最佳矫正视力(BCVA)字母评分平均提高13.9,非研究眼提高6.3,但作者认为改善幅度在极低视力眼的重测变异范围内,且可能与学习效应有关。
要点
- 12例BCD患者接受视网膜下注射rAAV2-hCYP4V2,未观察到与治疗相关的严重不良事件,1例出现轻度眼内炎症。
- 12个月时研究眼BCVA字母评分平均提高13.9,非研究眼提高6.3,作者认为改善幅度在极低视力眼的重测变异范围内。
- 作者认为双眼BCVA改善可能与学习效应有关,研究眼改善更大可能与其为视力更差眼有关。
核心结论
- 这项开放标签、探索性非随机临床试验在12个月随访中未发现与基因治疗相关的严重安全性问题。
- 虽然观察到BCVA改善,但改善幅度在极低视力眼通常可见的重测变异范围内,且研究眼与非研究眼的BCVA改善均可能与学习效应有关,研究眼改善更大可能与其为视力更差眼有关。
研究设计与样本
- 开放标签、剂量递增非随机临床试验,于2023年2月至2024年5月在中国2个研究点开展。
- 纳入经基因确诊携带双等位基因致病性CYP4V2变异的BCD患者,共12例,每个剂量组6例。
- 干预为基于视力字母评分选择较差眼行单眼单次视网膜下注射rAAV2-hCYP4V2,剂量为1.5×10^11或3.0×10^11总载体基因组,随访12个月。
主要发现
- 12例患者平均(SD)年龄40.5(7.1)岁,5例(42%)为女性。
- 未观察到与治疗相关的严重不良事件,但1例参与者出现轻度眼内炎症。
- 研究眼基线BCVA字母评分中位数(IQR)为34(10-53),相当于Snellen 20/200;非研究眼中位数(IQR)为60(40-67),约相当于Snellen 20/63。
- 12个月时研究眼字母评分平均(SD)提高13.9(13.1),非研究眼提高6.3(7.4)。
- 12个月时研究眼BCVA中位数(IQR)为53(37-64)(约相当于Snellen 20/80),非研究眼为62(42-70)(约相当于Snellen 20/50)。
局限性
- 作者指出BCVA改善幅度在极低视力眼通常可见的重测变异范围内。
- 作者指出研究眼与非研究眼的BCVA改善均可能与学习效应有关,研究眼改善更大可能与其为视力更差眼有关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bietti crystalline dystrophy (BCD) is a severe genetic retinopathy caused by variants in the CYP4V2 gene. Currently, there is no approved treatment for BCD. OBJECTIVE: To evaluate safety and vision outcomes following gene therapy with adeno-associated virus (AAV) encoding CYP4V2 (rAAV-hCYP4V2, NGGT001 [Next Generation Gene Therapeutics]). DESIGN, SETTING, AND PARTICIPANTS: This open-label, dose-escalation nonrandomized clinical trial was conducted from February 2023 to May 2024 at 2 study sites in China. Patients with genetically confirmed biallelic disease-linked CYP4V2 variants received subretinal injections of rAAV2-hCYP4V2 at 1 of 2 dosage levels and were followed up for 12 months. INTERVENTION: A single unilateral injection of 1.5 × 1011 or 3.0 × 1011 total vector genomes of recombinant AAV-hCYP4V2 in the worse eye, based on visual acuity letter score. MAIN OUTCOMES AND MEASURES: The primary outcome was safety, assessed by clinical examination of ocular inflammation and evaluated by routine clinical chemistry and immunogenicity testing. Secondary outcomes were changes in visual function from baseline in best-corrected visual acuity (BCVA), microperimetry, and contrast sensitivity 12 months after treatment. RESULTS: Among 12 patients with BCD (6 patients per dose group), mean (SD) patient age was 40.5 (7.1) years, and 5 patients (42%) were female. No severe adverse events related to the treatment were observed. However, mild intraocular inflammation was noted in 1 participant. The median (IQR) baseline BCVA letter score for the study eye was 34 (10-53), equivalent to 20/200 Snellen, while the nonstudy eye had a median (IQR) BCVA of 60 (40-67), equivalent to approximately 20/63 Snellen. At 12 months, the study eye improved by a mean (SD) letter score of 13.9 (13.1) compared with 6.3 (7.4) in the nonstudy eye. The 12-month median (IQR) BCVA for the study eye was 53 (37-64) (equivalent to approximately 20/80 Snellen) and 62 (42-70) (approximately 20/50 Snellen) for the nonstudy eye. CONCLUSIONS AND RELEVANCE: This open-label, exploratory nonrandomized clinical trial identified no serious safety concerns related to gene therapy over 12 months' follow-up among patients with BCD. While improvement in BCVA was noted, the magnitude was within test-retest values typically noted in eyes with very low levels of visual acuity, and BCVA improvement in both the study and nonstudy eyes could be related to a learning effect, with greater improvement in the study eye possibly related to study eyes' being the worse-seeing eye. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06302608.
引用
- Chen X, Liu X, Cui S, et al. Safety and Vision Outcomes Following Gene Therapy for Bietti Crystalline Dystrophy: A Nonrandomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 39786763. doi:10.1001/jamaophthalmol.2024.5619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。